This analysis examines underrepresentation of minority groups in breast cancer trials, suggesting implications for health equity.
Although race/ethnicity reporting has improved, minority populations remain gravely underrepresented in breast cancer clinical trials, limiting the generalizability of trial results in these populations.
No takes yet. Share an insight, caveat, or question.
Dimaano et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: